News Releases
Cannabix Technologies to Present Multi-Drug Breath Technology at BC Centre for Excellence on Substance Use Disorders
November 13, 2026
Vancouver, British Columbia, November 13, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana, multi-drug, and alcohol breath testing technologies, is pleased to announce that its Chief Scientific Officer, Dr. Raj Attariwala, will be presenting the Company's emerging multi-drug breath testing technology at the BC Centre for Excellence conference on substance use disorder being held in Vancouver, British Columbia on November 13.
The event is hosted by the BC Centre for Excellence, a world-renowned research and public health organization headed by Dr. Julio Montaner, whose pioneering treatments helped establish the global UNAIDS framework for combating HIV/AIDS. The conference will bring together physicians, researchers, addiction specialists, public health leaders and healthcare policy stakeholders to discuss current and emerging approaches to substance use disorder management, healthcare delivery and evidence-based public policy
During the presentation, Dr. Attariwala will discuss recent Cannabix findings demonstrating the ability of the Company’s Multi-Drug Breath Test platform to detect delta-9 THC and other illicit drugs in breath. These include the detection of traces of amphetamines/methamphetamines, cocaine, and opioids such as fentanyl. These findings highlight the broader potential of the Cannabix Breath Collection Unit (BCU) platform as a standardized breath collection technology that could support future multi-analyte testing approaches and scientific breath initiatives.
"We are pleased to be invited to this important forum and engage with leading clinicians, researchers and public health professionals working in the field of substance use disorders," stated Dr. Raj Attariwala. "Breath testing represents an accepted non-intrusive method for drug detection, and we believe our technology platform can be a non-invasive and convenient method for collecting valuable biological information to support substance abuse monitoring programs and even be used to help identify new street drugs."
Disclaimer:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
